Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
ONVO's Cash-to-Debt is ranked higher than
86% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. ONVO: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ONVO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1  Med: N/A Max: 43000
Current: No Debt
0.1
43000
Equity-to-Asset 0.93
ONVO's Equity-to-Asset is ranked higher than
95% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. ONVO: 0.93 )
Ranked among companies with meaningful Equity-to-Asset only.
ONVO' s Equity-to-Asset Range Over the Past 10 Years
Min: -7.39  Med: 0.93 Max: 0.96
Current: 0.93
-7.39
0.96
Interest Coverage No Debt
ONVO's Interest Coverage is ranked higher than
86% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. ONVO: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ONVO' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 30.00
Beneish M-Score: 0.30
WACC vs ROIC
17.53%
-8735.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -915.73
ONVO's Operating Margin % is ranked lower than
91% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. ONVO: -915.73 )
Ranked among companies with meaningful Operating Margin % only.
ONVO' s Operating Margin % Range Over the Past 10 Years
Min: -5448.28  Med: -3955.84 Max: -778.53
Current: -915.73
-5448.28
-778.53
Net Margin % -911.80
ONVO's Net Margin % is ranked lower than
91% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. ONVO: -911.80 )
Ranked among companies with meaningful Net Margin % only.
ONVO' s Net Margin % Range Over the Past 10 Years
Min: -6820.05  Med: -4453.41 Max: -911.8
Current: -911.8
-6820.05
-911.8
ROE % -58.43
ONVO's ROE % is ranked lower than
75% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. ONVO: -58.43 )
Ranked among companies with meaningful ROE % only.
ONVO' s ROE % Range Over the Past 10 Years
Min: -120.28  Med: -69.58 Max: -58.43
Current: -58.43
-120.28
-58.43
ROA % -54.03
ONVO's ROA % is ranked lower than
76% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. ONVO: -54.03 )
Ranked among companies with meaningful ROA % only.
ONVO' s ROA % Range Over the Past 10 Years
Min: -3700  Med: -77.23 Max: -54.03
Current: -54.03
-3700
-54.03
ROC (Joel Greenblatt) % -989.76
ONVO's ROC (Joel Greenblatt) % is ranked lower than
84% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. ONVO: -989.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ONVO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11894.96  Med: -2682.13 Max: -989.76
Current: -989.76
-11894.96
-989.76
GuruFocus has detected 2 Warning Signs with Organovo Holdings Inc $ONVO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ONVO's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ONVO Guru Trades in Q2 2016

Paul Tudor Jones 41,741 sh (+39.73%)
» More
Q3 2016

ONVO Guru Trades in Q3 2016

Jim Simons 82,063 sh (New)
Paul Tudor Jones 21,553 sh (-48.36%)
» More
Q4 2016

ONVO Guru Trades in Q4 2016

Paul Tudor Jones 31,035 sh (+43.99%)
Jim Simons Sold Out
» More
Q1 2017

ONVO Guru Trades in Q1 2017

Paul Tudor Jones 75,000 sh (+141.66%)
» More
» Details

Insider Trades

Latest Guru Trades with ONVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325414    SIC: 2836
Compare:NAS:QTNT, NAS:SRDX, NAS:OXFD, NAS:MGEN, NAS:RDNT, NAS:PACB, NYSE:NVTA, OTCPK:EPGNF, NAS:NVDQ, NYSE:ENZ, NAS:FLDM, OTCPK:CBIS, NAS:AIQ, AMEX:SENS, NAS:TRIB, NAS:FLGT, NAS:PMD, NAS:CTSO, NAS:VRML, NAS:TTOO » details
Traded in other countries:4OR.Germany, ONVO.Switzerland, 0R02.UK,
Headquarter Location:USA
Organovo Holdings Inc is a development-stage company. It is engaged in developing and commercializing functional human tissues.

Organovo Holdings Inc is incorporated in Delaware on April 2007. The Company is a development-stage company. It is engaged in developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company intend to introduce a paradigm shift in the approach to the generation of three-dimensional human tissues, by utilizing its proprietary platform technology to create human tissue constructs in 3D that mimic native human tissue composition and architecture. The Company is subject to various laws and regulations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, emissions and wastewater discharges, and the use and disposal of hazardous or potentially hazardous substances used in connection with research, including infectious disease agents.

Top Ranked Articles about Organovo Holdings Inc

Organovo Collaborates With University of Virginia to Develop Bioprinted Tissues for Volumetric Muscle Loss Injury
Organovo Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Organovo Announces CEO Transition
Organovo and Its Customers Present Data Supporting 3D Bioprinted Liver and Kidney Tissues for Drug Toxicity Testing

SAN DIEGO, March 13, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced eight presentations at the Society of Toxicology’s (“SOT”) 56th Annual Meeting and ToxExpo, March 12–16, 2017, in Baltimore.  These presentations demonstrate the broad applicability of Organovo’s ExViveTM 3D Bioprinted Human Liver and Kidney Tissues for the assessment of drug safety and the detection of multiple clinically-relevant modes of liver injury and kidney toxicity.  In addition, Organovo has been invited to speak at a scientific symposium on next-generation models for toxicology.
“We’re pleased by the strong early feedback on our newest product, the ExVive Human Kidney Tissue, and the ongoing uptake and validation of ExVive Human Liver Tissue by our customers and partners,” said Dr. Sharon Presnell, chief scientific officer, Organovo.  â€œThe commercial launch of our kidney proximal tubule model, in addition to our recent peer-reviewed publication highlighting its potential to become a key preclinical model for in vitro kidney toxicity testing, demonstrates our commitment to delivering novel tissue models using our platform technology.  We are expanding our portfolio by adding new tissues and by validating the use of our existing tissues across a broader set of applications.  The unique ability of our human liver model to reveal mechanisms of action for drug-induced livery injury (“DILI”) and model key aspects of chronic, progressive liver diseases such as fibrosis continues to put us at the forefront of in vitro human tissue modeling.” "Our powerful and versatile technology platform delivers 3D bioprinted tissues that provide an accurate, predictive and reproducible model of human liver and kidney biology for preclinical toxicity testing,” said Paul Gallant, general manager, Organovo.  “Customer adoption of our NovoView Preclinical Safety Services for hepatoxicity testing continues to be strong, with a growing list of applications and use cases driving market adoption including investigative toxicology, evaluation of different compound modalities and fibrosis modeling for drug discovery.  The demand for our drug safety testing services has been growing since its introduction, and long-term market adoption is expected to be robust given the significant gap it closes against traditional preclinical models.  At this year’s SOT Annual Meeting, we will build on our sales momentum by continuing to show that our 3D bioprinted tissues effectively model in vivo composition and physiology.” The presented data supports the use of the ExVive Human Liver and Kidney Tissue Models in: Differentiating high-risk compounds from low-risk to evaluate the multiple pathways and mechanisms of DILI. Identifying the metabolite-driven tox mechanisms of compounds such as acetaminophen in a concentration- and dose-dependent manner, thereby modeling tissue-level clinical outcomes in vitro.Characterizing the role of Kupffer cells (KCs) in modulating the outcome of drug-induced liver fibrosis.Demonstrating sustained metabolic capacity over time in terms of metabolic enzyme expression, metabolite formation, and gene expression levels to assess slow developing DILI toxicities.Illustrating the multiple mechanisms of nephrotoxicity to evaluate the progression and subsequent recovery of tissue-level injury.Assessing the expression, polarized localization and function of renal transporters involved in drug-induced renal toxicity. In addition, the Colgate-Palmolive Award for Student Research Training in Alternative Methods, which is supported by Organovo, will be presented to a doctoral candidate to study the dose-dependent impact of an environmental toxin and the underlying mechanisms using ExVive Human Liver Tissue. The presentations are as follows:    Scientific Symposium   Title: Utilization of Bioprinted Human Liver Tissues for Toxicology Applications and Disease ModelingDate: March 13, 11:10 a.m. - 11:45 a.m. ET, Ballroom IIPresenter: Rhiannon Hardwick, Ph.D., Organovo   Exhibitor-Hosted Sessions   Title: Simplifying the Complex:  Using 3D Bioprinted Kidney Tissue to Unravel the Intricate Mechanisms of Drug-Induced NephrotoxicityDate: March 13, 4:30 p.m. - 5:30 p.m. ET, Room 340Presenter: Deborah G. Nguyen, Ph.D., Organovo   Title: The Advantages of ExViveTM 3D Bioprinted Liver Tissue in Elucidating Clinically Relevant Mechanisms of Drug-Induced HepatoxicityDate: March 15, 1:30 p.m. - 2:30 p.m. ET, Room 340Presenters: Sharon Collins Presnell, Ph.D., Organovo  Leah M. Norona, Doctoral Candidate, The University of North Carolina at Chapel Hill   Poster Presentations   Title: Utilization of the ExVive Human Liver Tissue Model to Assess Drug-Induced Liver Injury Across a Diverse Set of Chemical ClassesPresenter: Candace M. Crogan-Grundy, Ph.D., OrganovoPoster: 1246: Poster Board - P406   Title: Utilization of the ExVive Human Kidney Tissue Model of Proximal Tubule to Assess Nephrotoxicity Across a Diverse Set of Chemical ClassesPresenter: J. William Higgins, OrganovoPoster: 1804: Poster Board – P344   Title: Mechanistic Study of Acetaminophen-Induced Liver Injury Using a 3D Bioprinted Human Liver Tissue ModelPresenter:  Masato Ohbuchi, Ph.D., Astellas Pharma Inc.Poster: 1653: Poster Board – P105   Title:  3D Bioprinted Human Liver: Metabolic and Transcriptional CharacterizationPresenter: Andreas Baudy, Ph.D., Merck & Co., Inc.Poster: 3274: Poster Board – P243   Title:   Temporal Characterization of a 3D Bioprinted Model May Provide New Insight into Events Underlying Fibrotic Liver InjuryPresenter: Leah M. Norona, Doctoral Candidate, The University of North Carolina at Chapel HillPoster: 3373: Poster Board - P344   Exhibit Booth: March 13-15, 9:15 a.m. - 4:30 p.m. ET, Booth 2057, CC Exhibit Hall    About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications.  The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners.  Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost.  The Company’s ExVive Human Liver and Kidney Tissues are used in toxicology and other preclinical drug testing.  The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications.  In addition to numerous scientific publications, the Company’s technology has been featured in The Wall Street Journal, Time Magazine, The Economist, Forbes, and numerous other media outlets.  Organovo is changing the shape of life science research and transforming medical care.  Learn more at www.organovo.com.     Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties.  The factors that could cause the Company's actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products and services based on its technology; the expected benefits and efficacy of the Company's products, services and technology; the Company’s ability to successfully complete studies and provide the technical information required to support market acceptance of its products, services and technology, on a timely basis or at all; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies, including its use of third party distributors; the Company's ability to successfully complete the contracts and recognize the revenue represented by the contracts included in its previously reported total contract bookings and secure additional contracted collaborative relationships; the final results of the Company's preclinical studies may be different from the Company's studies or interim preclinical data results and may not support further clinical development of its therapeutic tissues; the Company may not successfully complete the required preclinical and clinical trials required to obtain regulatory approval for its therapeutic tissues on a timely basis or at all; and the Company’s ability to meet its fiscal year 2017 outlook and/or its long-range outlook.  These and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 9, 2016 and its Quarterly Report on Form 10-Q filed with the SEC on February 9, 2017.  You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made.  These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future.  Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.  
Investor Contact:

Steve Kunszabo
Organovo Holdings, Inc.
1 (858) 224-1092
[email protected]

Press Contact:

Jessica Yingling, Ph.D.
Little Dog Communications
1 (858) 480-2411
[email protected]

Read more...
Organovo to Present at 29th Annual Roth Conference

SAN DIEGO, March 09, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced that Chief Financial Officer Craig Kussman is scheduled to speak at the 29th Annual Roth Conference in Laguna Nigel, Ca., on Tuesday, March 14th at 2:00 p.m. Pacific Time (PT).  The presentation will be simultaneously audio webcast at http://www.organovo.com.  The audio webcast will be archived for 90 days following the conference.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications.  The Company develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic and other partners.  Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost.  The Company’s ExVive Human Liver and Kidney Tissues are used in toxicology and other preclinical drug testing.  The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications.  In addition to numerous scientific publications, the Company’s technology has been featured in The Wall Street Journal, Time Magazine, The Economist, Forbes, and numerous other media outlets.  Organovo is changing the shape of life science research and transforming medical care.  Learn more at www.organovo.com. Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties.  The factors that could cause the Company's actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products and services based on its technology; the expected benefits and efficacy of the Company's products, services and technology; the Company’s ability to successfully complete studies and provide the technical information required to support market acceptance of its products, services and technology, on a timely basis or at all; the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies, including its use of third party distributors; the Company's ability to successfully complete the contracts and recognize the revenue represented by the contracts included in its previously reported total contract bookings and secure additional contracted collaborative relationships; the final results of the Company's preclinical studies may be different from the Company's studies or interim preclinical data results and may not support further clinical development of its therapeutic tissues; the Company may not successfully complete the required preclinical and clinical trials required to obtain regulatory approval for its therapeutic tissues on a timely basis or at all; and the Company’s ability to meet its fiscal year 2017 outlook and/or its long-range outlook.  These and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 9, 2016 and its Quarterly Report on Form 10-Q filed with the SEC on February 9, 2017.  You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made.  These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future.  Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.
Investor Contact:

Steve Kunszabo
Organovo Holdings, Inc.
1 (858) 224-1092
[email protected]

Press Contact:
Jessica Yingling
Little Dog Communications
1 (858) 480-2411
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 4.18
ONVO's PB Ratio is ranked lower than
61% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. ONVO: 4.18 )
Ranked among companies with meaningful PB Ratio only.
ONVO' s PB Ratio Range Over the Past 10 Years
Min: 2.05  Med: 7.73 Max: 63.4
Current: 4.18
2.05
63.4
PS Ratio 67.86
ONVO's PS Ratio is ranked lower than
97% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. ONVO: 67.86 )
Ranked among companies with meaningful PS Ratio only.
ONVO' s PS Ratio Range Over the Past 10 Years
Min: 64.52  Med: 249.58 Max: 2180
Current: 67.86
64.52
2180
EV-to-EBIT -6.27
ONVO's EV-to-EBIT is ranked lower than
99.99% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. ONVO: -6.27 )
Ranked among companies with meaningful EV-to-EBIT only.
ONVO' s EV-to-EBIT Range Over the Past 10 Years
Min: -27.3  Med: -7.15 Max: 46.4
Current: -6.27
-27.3
46.4
EV-to-EBITDA -6.47
ONVO's EV-to-EBITDA is ranked lower than
99.99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. ONVO: -6.47 )
Ranked among companies with meaningful EV-to-EBITDA only.
ONVO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -27.7  Med: -7.35 Max: 44.8
Current: -6.47
-27.7
44.8
Current Ratio 16.20
ONVO's Current Ratio is ranked higher than
96% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. ONVO: 16.20 )
Ranked among companies with meaningful Current Ratio only.
ONVO' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 13.23 Max: 34
Current: 16.2
0.04
34
Quick Ratio 16.13
ONVO's Quick Ratio is ranked higher than
96% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. ONVO: 16.13 )
Ranked among companies with meaningful Quick Ratio only.
ONVO' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 13.21 Max: 34
Current: 16.13
0.04
34
Days Inventory 159.60
ONVO's Days Inventory is ranked lower than
77% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. ONVO: 159.60 )
Ranked among companies with meaningful Days Inventory only.
ONVO' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 159.6
Current: 159.6
0
159.6
Days Sales Outstanding 94.79
ONVO's Days Sales Outstanding is ranked lower than
75% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. ONVO: 94.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
ONVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.4  Med: 56.58 Max: 94.79
Current: 94.79
49.4
94.79
Days Payable 340.92
ONVO's Days Payable is ranked higher than
94% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. ONVO: 340.92 )
Ranked among companies with meaningful Days Payable only.
ONVO' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0 Max: 340.92
Current: 340.92
0
340.92

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4.60
ONVO's Price-to-Net-Cash is ranked higher than
78% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.15 vs. ONVO: 4.60 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ONVO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.48  Med: 8.16 Max: 47.25
Current: 4.6
3.48
47.25
Price-to-Net-Current-Asset-Value 4.45
ONVO's Price-to-Net-Current-Asset-Value is ranked higher than
73% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. ONVO: 4.45 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ONVO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.44  Med: 8.02 Max: 42
Current: 4.45
3.44
42
Price-to-Tangible-Book 4.19
ONVO's Price-to-Tangible-Book is ranked higher than
56% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. ONVO: 4.19 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ONVO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.22  Med: 7.66 Max: 35.66
Current: 4.19
3.22
35.66
Price-to-Median-PS-Value 0.27
ONVO's Price-to-Median-PS-Value is ranked higher than
91% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. ONVO: 0.27 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ONVO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.27  Med: 1.21 Max: 8.35
Current: 0.27
0.27
8.35
Earnings Yield (Greenblatt) % -15.93
ONVO's Earnings Yield (Greenblatt) % is ranked lower than
84% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. ONVO: -15.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ONVO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -16.38  Med: 2.6 Max: 3.9
Current: -15.93
-16.38
3.9

More Statistics

Revenue (TTM) (Mil) $3.97
EPS (TTM) $ -0.37
Beta2.55
Short Percentage of Float16.57%
52-Week Range $2.48 - 4.99
Shares Outstanding (Mil)104.41
» More Articles for ONVO

Headlines

Articles On GuruFocus.com
Organovo Collaborates With University of Virginia to Develop Bioprinted Tissues for Volumetric Muscl May 01 2017 
Organovo Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Apr 24 2017 
Organovo Announces CEO Transition Apr 11 2017 
Organovo and Its Customers Present Data Supporting 3D Bioprinted Liver and Kidney Tissues for Drug T Mar 13 2017 
Organovo to Present at 29th Annual Roth Conference Mar 09 2017 
Why 3D Printing and Biotech Will Be Good Bets in 2017 Feb 23 2017 
Investors Are 3-D Printing Their Gains Nov 21 2016 
2015 Must-Buys In Biotech Sector Feb 02 2015 
Why Organovo is A Safe Buy? Dec 18 2014 
Is Organovo A Safe Buy? Dec 08 2014 

More From Other Websites
3 Stocks That Could Put Amazon.com's Returns to Shame May 24 2017
Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues at World Advanced... May 18 2017
Organovo Holdings, Inc. breached its 50 day moving average in a Bullish Manner : ONVO-US : May 17,... May 17 2017
Organovo Announces Release Date for Fiscal Fourth-Quarter 2017 Financial Results May 17 2017
Here's Why Organovo Holdings Stock Fell 5.2% In April May 11 2017
Organovo Holdings, Inc. – Value Analysis (NASDAQ:ONVO) : May 3, 2017 May 03 2017
Organovo Collaborates With University of Virginia to Develop Bioprinted Tissues for Volumetric... May 01 2017
Organovo Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Apr 24 2017
Why Organovo Holdings Inc Shareholders Have Something to Worry About Apr 18 2017
Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents Apr 12 2017
Organovo Holdings CEO Leaves: Should Investors Be Worried? Apr 12 2017
Organovo Announces CEO Transition Apr 11 2017
What's Next for Organovo Holdings Inc.? Apr 11 2017
ETFs with exposure to Organovo Holdings, Inc. : April 7, 2017 Apr 07 2017
Organovo and Its Customers Present Data Supporting 3D Bioprinted Liver and Kidney Tissues for Drug... Mar 13 2017
Organovo to Present at 29th Annual Roth Conference Mar 09 2017
Here's Why Organovo Holdings Inc Dipped 15.7% in February Mar 06 2017
3 Stocks to Avoid in Biotech Feb 28 2017
Better Buy: Organovo Holdings, Inc. vs. United Therapeutics Corporation Feb 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)